European Archives - Page 84 of 1138 - European Medical Journal

Investigating Probiotics for Managing Atopic Dermatitis in Infants

Recent research highlights the role of gut microbiota in atopic dermatitis pathogenesis.

EMJ Dermatology 13 [Supplement 1] 2025

Nemolizumab is an anti-IL-31Rα monoclonal antibody that has demonstrated clinical efficacy in two global Phase III studies (ARCADIA-1 and…

Nemolizumab in Atopic Dermatitis

Nemolizumab is an anti-IL-31Rα monoclonal antibody that has demonstrated clinical efficacy in two global Phase III studies (ARCADIA-1 and…

Butter vs. Plant-Based Oils: Groundbreaking Study Reveals Butter Linked to Higher Death Rates

Butter linked to higher mortality; plant-based oils reduce death risks. Study urges dietary swaps for long-term health.

Cartoon brain on green background

Phase 2 trial begins for psychedelic-based depression treatment

A DMT-based treatment for people with treatment-resistant depression (TRD) has entered Phase 2 clinical trials.

Niraparib Shows Promise in Ovarian Cancer: ESGO 2025

The MITO 40 study, presented at ESGO 2025, highlights promising results for Niraparib as a maintenance treatment in ovarian cancer patients with no residual disease post-surgery.

Updated ATHENA-MONO Data Confirms Rucaparib Benefits: ESGO 2025

Rucaparib showed longer progression-free survival, chemotherapy-free interval, and time to first subsequent treatment in advanced ovarian cancer patients, according to updated results from the ATHENA-MONO study.

Treatment Advances in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

The primary treatment for intermediate and high-risk NMIBC includes transurethral resection of the bladder tumour.

Chronic Rhinosinusitis Linked to Lung Disease

A new study has found strong associations between chronic rhinosinusitis and chronic airflow limitation, lower airway symptoms, and smoking-related lung diseases.

Accuracy of Preoperative Tumour Size Assessment in Cervical Cancer: ESGO 2025

ESGO 2025 study reveals overestimation of preoperative tumour size in stage IB2 cervical cancer, influencing adjuvant therapy decisions.